Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

Petrelli, Fausto; Borgonovo, Karen; Barni, Sandro

doi:10.1517/14656561003796562

Cited by 103 publications

(57 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, compared with paclitaxel, Abraxane can improve drug delivery into the tumor (8,9). The antiangiogenesis activity of paclitaxel has been observed even at low concentrations, which did not affect cellular microtubule assembly (10,11).…”

mentioning

confidence: 99%

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

Sun¹,

Yan²,

Liu³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

mentioning

confidence: 99%

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

Sun¹,

Yan²,

Liu³

et al. 2010

J Nucl Med

View full text Add to dashboard Cite

“…46 The caveolae (endothelium transcytosis vesicles)-induced accumulation of an albumin-bound nanomedicine (Abraxane) is initiated by the binding of albumin to a cell surface glycoprotein receptor, suggesting that caveolae targeting might provide a universal portal to pump drugs out of the blood into nearby tissue. 47 Moreover, arginine-glycine-aspartic acid (RGD) motif has been found to exhibit a strong affinity and selectivity for cell surface in many proteins, thus proclaiming it to be a suitable ligand for tumor targeting by therapeutic NPs. 48 …”

Section: Targeting the Tumor Microenvironmentmentioning

confidence: 99%

Nanotechnology-based approaches in anticancer research

Jabir¹,

Tabrez²,

Ashraf³

et al. 2012

IJN

149

View full text Add to dashboard Cite

Cancer is a highly complex disease to understand, because it entails multiple cellular physiological systems. The most common cancer treatments are restricted to chemotherapy, radiation and surgery. Moreover, the early recognition and treatment of cancer remains a technological bottleneck. There is an urgent need to develop new and innovative technologies that could help to delineate tumor margins, identify residual tumor cells and micrometastases, and determine whether a tumor has been completely removed or not. Nanotechnology has witnessed significant progress in the past few decades, and its effect is widespread nowadays in every field. Nanoparticles can be modified in numerous ways to prolong circulation, enhance drug localization, increase drug efficacy, and potentially decrease chances of multidrug resistance by the use of nanotechnology. Recently, research in the field of cancer nanotechnology has made remarkable advances. The present review summarizes the application of various nanotechnology-based approaches towards the diagnostics and therapeutics of cancer.

show abstract

“…[5][6][7] The US Food and Drug Administration has approved for cancer therapy the use of doxorubicin encapsulated in liposomes (Doxil) and paclitaxel attached to nanoparticles (Abraxane). 8,9 In cancer chemotherapy, the clinician aims to achieve a good therapeutic index, which is the ratio of the lethal dose for 50% of the population to the minimum effective dose for 50% of the population. 10 But cancer is most often…”

Section: Introductionmentioning

confidence: 99%

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Berce¹,

Lucan²,

Petrushev

et al. 2016

IJN

View full text Add to dashboard Cite

Introduction The present study aimed at evaluating the biodistribution of Tween ® 20-gold nanoparticle (GNP) conjugates and their potential toxicity on the bone marrow before moving on to Phase I clinical trials. Materials and methods Tween ® 20-conjugated GNPs were injected intravenously for 21 days in male Crl:CD1(ICR) mice. Body weight of the mice was evaluated each day. After the sub-chronic Tween ® 20-GNPs administration, blood samples were harvested, and a full blood count was done individually. Total Au quantity from all major organs was assessed using inductively coupled plasma mass spectrometry. One femur and the sternum obtained from each animal were used for histological assessment. Results Our data showed that the Tween ® 20-GNP conjugates were found in large quantities in the bladder. Au was shown to accumulate in the hematopoietic bone tissue, with significant side effects such as leucopoiesis and megakaryopoiesis. The mice had a higher white blood cell and platelet count as opposed to the control group. This suggested that the previously described leukopenic effects of isoflurane were overridden by the leucopoietic effects of Tween ® 20-GNPs. Conclusion It was uncertain whether the mice were reactive to Au as it is a foreign substance to the tissues or whether the side effects observed were a precursor condition of a more severe hematological condition. Au was found to be hepatotoxic, urging the need for further studies in order to achieve better in vivo compliance and exploit the immense potential of GNPs in cancer pharmacology.

show abstract

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

Cited by 103 publications

References 48 publications

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

Nanotechnology-based approaches in anticancer research

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Contact Info

Product

Resources

About

Targeted delivery for breast cancer therapy: the history of nanoparticle-albumin-bound paclitaxel

Cited by 103 publications

References 48 publications

18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy

18F-FPPRGD2 and 18F-FDG PET of Response to Abraxane Therapy

Nanotechnology-based approaches in anticancer research

In vivo assessment of bone marrow toxicity by gold nanoparticle-based bioconjugates in Crl:CD1(ICR) mice

Contact Info

Product

Resources

About

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy

¹⁸F-FPPRGD2 and ¹⁸F-FDG PET of Response to Abraxane Therapy